More than 90 percent of cervical cancers have been associated with human papillomaviruses (HPVs). Two HPV oncogenic proteins, E6 and E7, are important in the induction and maintenance of cellular transformation and are co-expressed in most HPV- containing cervical cancers. Therefore, vaccines or immunotherapies targeting E6 and E7 proteins will provide an opportunity to prevent and treat HPV-associated cervical malignancies. The destruction of tumor cells will most likely require induction of a tumor specific cytotoxic T lymphocyte (CTL) response as well as potentially a tumor specific T helper (Th) response. Studies in vitro indicate that T cell responses vary qualitatively and quantitatively depending on two parameters: 1) the density of peptide-MHC complexes on the surface of antigen presenting cells, and 2) the nature of co-stimulatory signals delivered to the T cell in conjunction with T cell receptor engagement. Based on this improved understanding, the applicant has identified potential strategies to optimize T cell activation by modifying both parameters in vivo. These strategies will utilize a vaccinia vector and E6 and E7 as the targeted tumor specific antigens. The broad objective of this application is to develop strategies to enhance E6 and E7 specific T cell responses by optimizing the activation of E6 and E7 specific T cells and to evaluate the potency of the vaccines in generating antitumor immunity against tumors expressing E6 and E7. Since the failure of the immune system to reject tumors is frequently attributed to insufficient CD4+ T help, the applicant will focus on strategies than enhance CD4+ helper T cell responses. Specifically, he plans to: 1) Construct recombinant vaccinia which increase the density of E6/E7 peptide MHC class II complexes by delivering chimeric E6/E7 into the MHC class II pathway. 2) Engineer double recombinant vaccines that will enable to co-expression of E6/E7 or Sig/E6/E7/LAMP-1 along with molecules capable of providing co-stimulatory signals to responding T cells. 3) Characterize the standard immunologic parameters of E6 and E7 specific responses generated by optimized recombinant vaccinia vaccines. 4) Generate E6 and E7 expressing murine tumors for in vivo protection and treatment experiments. 5) Perform head-to-head comparison of various E6, E7 and chimeric E6E7 vaccines in antitumor immunity using E6 and E7 expressing murine model tumors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA072631-02
Application #
2633943
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Wong, May
Project Start
1997-01-01
Project End
2001-12-31
Budget Start
1998-01-01
Budget End
1998-12-31
Support Year
2
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Pathology
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Zeng, Qi; Peng, Shiwen; Monie, Archana et al. (2011) Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents. Hum Gene Ther 22:809-19
Huang, Bruce; Mao, Chih-Ping; Peng, Shiwen et al. (2007) Intradermal administration of DNA vaccines combining a strategy to bypass antigen processing with a strategy to prolong dendritic cell survival enhances DNA vaccine potency. Vaccine 25:7824-31
Hung, Chien-Fu; Cheng, Wen-Fang; He, Liangmei et al. (2003) Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes. Cancer Res 63:2393-8
Cheng, W F; Hung, C F; Lin, K Y et al. (2003) CD8+ T cells, NK cells and IFN-gamma are important for control of tumor with downregulated MHC class I expression by DNA vaccination. Gene Ther 10:1311-20
Cheng, Wen-Fang; Hung, Chien-Fu; Hsu, Keng-Fu et al. (2002) Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum Gene Ther 13:553-68
Hung, Chien-Fu; He, Liangmei; Juang, Jeremy et al. (2002) Improving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen. J Virol 76:2676-82
Chen, C H; Wang, T L; Ji, H et al. (2001) Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene. Gene Ther 8:128-38
Cheng, W F; Hung, C F; Chai, C Y et al. (2001) Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene. J Immunol 166:6218-26
Hung, C F; Cheng, W F; Hsu, K F et al. (2001) Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res 61:3698-703
Hung, C F; Cheng, W F; Chai, C Y et al. (2001) Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen. J Immunol 166:5733-40

Showing the most recent 10 out of 21 publications